Medsenic SAS, a biopharmaceutical company dedicated to the treatment of autoimmune diseases with arsenic derivatives, announced today that it raised funds from two investment actors, Alsace Capital (Cap Innov’Est) and Fa Dièse (Fa Dièse 3). The CNRS (French Centre National de la Recherche Scientifique), through its subsidiary Fist SA is also becoming shareholder of the company. Others private investors are participating, Medsenic still being significantly supported by its exi